Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.

[1]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[2]  L. Tsai,et al.  Structure and Regulation of the CDK5-p25nck5a Complex , 2001 .

[3]  P. Traxler,et al.  ATP site‐directed competitive and irreversible inhibitors of protein kinases , 2000, Medicinal research reviews.

[4]  Zhijian Xiao,et al.  Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China , 2002, Leukemia & lymphoma.

[5]  F. Guengerich,et al.  Oxidation of indole by cytochrome P450 enzymes. , 2000, Biochemistry.

[6]  R. Maccioni,et al.  The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. , 2001, European journal of biochemistry.

[7]  S. Safe,et al.  Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). , 2002, International journal of oncology.

[8]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[9]  Doris Marko,et al.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases , 1999, Nature Cell Biology.

[10]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[11]  Li-Huei Tsai,et al.  A decade of CDK5 , 2001, Nature Reviews Molecular Cell Biology.

[12]  L. Meijer,et al.  Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells , 2001, British Journal of Cancer.

[13]  A. Westwell,et al.  The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? , 2002, Current pharmaceutical design.

[14]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[15]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[16]  Ana Martínez,et al.  Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? , 2002 .

[17]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[18]  Laurent Meijer,et al.  Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. , 2004, Biochimica et biophysica acta.

[19]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[20]  L. Tsai,et al.  Cdk5 behind the wheel: a role in trafficking and transport? , 2002, Trends in cell biology.

[21]  C. Elferink.  Aryl hydrocarbon receptor-mediated cell cycle control. , 2003, Progress in cell cycle research.

[22]  M. Gilman,et al.  Expression and isolation of antimicrobial small molecules from soil DNA libraries. , 2001, Journal of Molecular Microbiology and Biotechnology.

[23]  R. Rieke,et al.  New Synthetic Route to 6-Nitroisatin via Nitration of 3-Indolealdehyde , 1962 .

[24]  L. Meijer,et al.  Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest , 2001, Oncogene.

[25]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[26]  Kirk W. Johnson,et al.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. , 2002, Diabetes.

[27]  Laurent Meijer,et al.  Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. , 2002, Biochemical pharmacology.

[28]  Ana Martínez,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[29]  I. Hardcastle,et al.  Designing inhibitors of cyclin-dependent kinases. , 2002, Annual review of pharmacology and toxicology.

[30]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[31]  B. Strooper,et al.  Alzheimer's disease: Mental plaque removal , 2003, Nature.

[32]  Kazuyuki Takata,et al.  Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo , 2003, Neuron.

[33]  Gerhard Eisenbrand,et al.  Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine , 1992 .

[34]  C. Cooksey.  Tyrian Purple: 6,6’-Dibromoindigo and Related Compounds , 2001, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[35]  James P. Snyder,et al.  Pseudoreceptor Modeling: The Construction of Three-Dimensional Receptor Surrogates , 1995 .

[36]  M. Barbacid,et al.  Genetic Analysis of Mammalian Cyclin-Dependent Kinases and Their Inhibitors , 2000, Biological chemistry.

[37]  G Eisenbrand,et al.  Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. , 2001, Structure.

[38]  H. Takigami,et al.  Indirubin and Indigo Are Potent Aryl Hydrocarbon Receptor Ligands Present in Human Urine* , 2001, The Journal of Biological Chemistry.

[39]  Jacques Dumas,et al.  Protein kinase inhibitors: emerging pharmacophores 1997 - 2000 , 2001 .

[40]  A. Hanberg,et al.  A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  L. Johnson,et al.  Structure-based design of cyclin-dependent kinase inhibitors. , 2002, Pharmacology & therapeutics.

[42]  D. Cooper,et al.  Protein Kinases as Therapeutic Targets , 2000, Pharmaceutical Research.